Mississippi is currently home to 401 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Jackson, Tupelo, Hattiesburg and Flowood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
12/15/2022
Locations: Precise Research Centers, Flowood, Mississippi
Conditions: Schizophrenia
Register for Updates
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
NCT03476980
Recruiting
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Gender:
All
Ages:
Between 22 months and 42 months
Trial Updated:
11/22/2022
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Neurodevelopmental Abnormality
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: The University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: The National Diabetes & Obesity Research Institute, Biloxi, Mississippi
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
It's Native: Nudging Healthy Ways
NCT05470296
Recruiting
Native Americans suffer disproportionately from chronic diseases that may be prevented by achieving a healthy diet, physical activity and weight. For this pilot study, the aim is to examine the effectiveness and feasibility of a standard lifestyle management program implemented in community based settings among Native Americans.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
08/09/2022
Locations: The University of Southern Mississippi, Hattiesburg, Mississippi
Conditions: Diet, Healthy, Physical Activity
Register for Updates
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT05048056
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2022, Ridgeland, Mississippi
Conditions: Atopic Dermatitis
Register for Updates
Telemedicine for PrEP Throughout Mississippi
NCT03840382
Recruiting
This study will develop and test a program to deliver PrEP care in underserved communities in Mississippi (MS) through telemedicine, distance-based, clinical care delivered in local community based organizations (CBOs). The intervention will be developed in collaboration with medical specialists at the University of Mississippi Medical Center (UMMC) and local CBO stakeholders (providers, administrators and patients). Approximately 75 individuals will be recruited from CBOs in MS. Participants wi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2022
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: HIV/AIDS
Register for Updates
Prostate Artery Embolization: Single Center Experience
NCT04766268
Recruiting
Benign prostatic hyperplasia (BPH) is an enlarged prostate gland from smooth muscle and glandular hyperplasia seen in the aging population with a prevalence of upto 90% in patients in the ninth decade. Lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) are the most common presenting symptoms of BPH. Patients are initially evaluated with a complete history and physical exam to rule out other causes of LUTS and assess the severity of LUTS with scoring systems such as the Amer... Read More
Gender:
Male
Ages:
45 years and above
Trial Updated:
02/22/2022
Locations: University of Mississippi Medical center, Jackson, Mississippi
Conditions: Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms
Register for Updates
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
NCT03545607
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 111, Jackson, Mississippi
Conditions: Ischemic Stroke
Register for Updates